Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18

被引:0
|
作者
Zhang, Yuanyuan [1 ,2 ]
Zeng, Hao [1 ,2 ]
Qi, Chang [1 ,2 ]
Tan, Sihan [1 ,2 ]
Huang, Qin [1 ,2 ]
Pu, Xin [1 ,2 ]
Suda, Kenichi [3 ]
Santarpia, Mariacarmela [4 ]
Tian, Panwen [1 ,2 ]
Li, Yalun [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Pulm & Crit Care Med, State Key Lab Resp Hlth & Multimorbid,Precis Med K, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Lung Canc Inst, Lung Canc Ctr, Chengdu, Peoples R China
[3] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Sayama, Japan
[4] Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy
基金
中国国家自然科学基金;
关键词
Non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); very rare mutations; targeted therapy; efficacy; MOLECULAR CHARACTERISTICS; NSCLC; RESISTANCE; AFATINIB; OSIMERTINIB;
D O I
10.21037/tlcr-24-113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Somatic mutations in epidermal growth factor receptor ( EGFR ) exon 18 are classified as uncommon or rare mutations in non -small cell lung cancer (NSCLC), in this context, other than G719X or E709X exon 18 mutations are even more rare and heterogeneous. In such scenario, first line treatment options are still debated. The aim of this study was to investigate the response of NSCLC patients harboring very rare exon 18 mutations to EGFR tyrosine kinase inhibitors (EGFR-TKIs). Methods: This retrospective descriptive study included 105 patients with NSCLC harboring mutations in EGFR exon 18 diagnosed at West China Hospital. The clinical response to EGFR-TKIs was evaluated according to different classifications of mutations in 45 NSCLC patients: 39 harboring G719X or E709X mutations and 6 harboring very rare mutations in EGFR exon 18. Results: Among 105 patients, 84% (88/105) harbored rare mutations in EGFR exon 18, including G719X and E709X mutations. The remaining 16% (17/105) had very rare mutations in EGFR exon 18, including E709_710delinsX and G724S. For the subsequent efficacy analysis of EGFR-TKI in 45 NSCLC patients, patients harboring very rare mutations achieved a favorable disease control rate (DCR) of 100% and had a median progression -free survival (PFS) of 17.2 months, which was not significantly different compared to patients harboring G719X or E709X (P=0.59). Conclusions: EGFR-TKIs showed great efficacy in terms of responses and survival in patients harboring exon 18 EGFR rare mutations. This may justify the use of targeted therapies as a potential treatment strategy for these patients.
引用
收藏
页码:875 / 884
页数:13
相关论文
共 50 条
  • [41] The landscape of EGFR exon 20 insertion mutations in Chinese patients with non-small cell lung cancer.
    Xu, Shun
    Fu, Zhichao
    CANCER RESEARCH, 2022, 82 (12)
  • [42] A Case of Non Small Cell Lung Cancer EGFR Mutation EXON 18 Positive With Poor Response to Targeted Therapy
    Felizardo, Margarida
    Matos, Claudia P.
    Furtado, Sofia T.
    Coelho, Jose P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S198 - S198
  • [43] Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
    Tian, Xueli
    Gu, Tingxuan
    Lee, Mee-Hyun
    Dong, Zigang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [44] CLINICAL CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER WITH EGFR GENE MUTATIONS IN EXON 20
    Miyanaga, A.
    Akagi, K.
    Takeuchi, S.
    Kurimoto, F.
    Iijima, Y.
    Yoshino, N.
    Mikami, I.
    Akiyama, H.
    Sakai, H.
    LUNG CANCER, 2009, 64 : S54 - S54
  • [45] Distribution Characteristics and Response Analysis of Non-Small Cell Lung Cancer Patients with EGFR Rare Mutations
    Liu, Y.
    Liu, H.
    Zhu, J.
    Li, H.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1087 - S1087
  • [46] Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations
    Kenmotsu, H.
    Imamura, C. K.
    Kawamura, T.
    Oyakawa, T.
    Omori, S.
    Nakashima, K.
    Wakuda, K.
    Ono, A.
    Taira, T.
    Naito, T.
    Murakami, H.
    Yamamoto, N.
    Takahashi, T.
    Tanigawara, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
    Li, Fenge
    Deng, Ligang
    Jackson, Kyle R.
    Talukder, Amjad H.
    Katailiha, Arjun S.
    Bradley, Sherille D.
    Zou, Qingwei
    Chen, Caixia
    Huo, Chong
    Chiu, Yulun
    Stair, Matthew
    Feng, Weihong
    Bagaev, Aleksander
    Kotlov, Nikita
    Svekolkin, Viktor
    Ataullakhanov, Ravshan
    Miheecheva, Natalia
    Frenkel, Felix
    Wang, Yaling
    Zhang, Minying
    Hawke, David
    Han, Ling
    Zhou, Shuo
    Zhang, Yan
    Wang, Zhenglu
    Decker, William K.
    Sonnemann, Heather M.
    Roszik, Jason
    Forget, Marie-Andree
    Davies, Michael A.
    Bernatchez, Chantale
    Yee, Cassian
    Bassett, Roland
    Hwu, Patrick
    Du, Xueming
    Lizee, Gregory
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [48] Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations A Review
    Passaro, Antonio
    Mok, Tony S. K.
    Attili, Ilaria
    Wu, Yi-Long
    Tsuboi, Masahiro
    de Marinis, Filippo
    Peters, Solange
    JAMA ONCOLOGY, 2023, 9 (08) : 1124 - 1131
  • [49] Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer
    Crintea, Andreea
    Constantin, Anne-Marie
    Motofelea, Alexandru C.
    Crivii, Carmen-Bianca
    Velescu, Maria A.
    Coseriu, Razvan L.
    Ilyes, Tamas
    Craciun, Alexandra M.
    Silaghi, Ciprian N.
    JOURNAL OF FUNCTIONAL BIOMATERIALS, 2023, 14 (09)
  • [50] Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations
    Li, Y-S.
    Jiang, B-Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27